Related Experiment Video
Updated: Apr 3, 2026

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies
Published on: August 29, 2017
JC polyomavirus mutants escape antibody-mediated neutralization
Upasana Ray1, Paola Cinque2, Simonetta Gerevini3
1Lab of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Abstract:
JC polyomavirus (JCV) persistently infects the urinary tract of most adults. Under conditions of immune impairment, JCV causes an opportunistic brain disease, progressive multifocal leukoencephalopathy (PML). JCV strains found in the cerebrospinal fluid of PML patients contain distinctive mutations in surface loops of the major capsid protein, VP1. We hypothesized that VP1 mutations might allow the virus to evade antibody-mediated neutralization. Consistent with this hypothesis, neutralization serology revealed that plasma samples from PML patients neutralized wild-type JCV strains but failed to neutralize patient-cognate PML-mutant JCV strains. This contrasted with serological results for healthy individuals, most of whom robustly cross-neutralized all tested JCV variants. Mice administered a JCV virus-like particle (VLP) vaccine initially showed neutralizing "blind spots" (akin to those observed in PML patients) that closed after booster immunization. A PML patient administered an experimental JCV VLP vaccine likewise showed markedly increased neutralizing titer against her cognate PML-mutant JCV. The results indicate that deficient humoral immunity is a common aspect of PML pathogenesis and that vaccination may overcome this humoral deficiency. Thus, vaccination with JCV VLPs might prevent the development of PML.
Insights
JC polyomavirus (JCV) causes progressive multifocal leukoencephalopathy (PML) in immunocompromised individuals. JCV VP1 mutations in PML patients evade antibodies, but JCV virus-like particle (VLP) vaccination may restore neutralizing immunity and prevent PML.
Area of Science:
- Virology
- Immunology
- Neuroscience
Background:
- JC polyomavirus (JCV) establishes persistent infections in the adult urinary tract.
- Immune suppression can lead to JCV-associated opportunistic brain disease, progressive multifocal leukoencephalopathy (PML).
- JCV strains from PML patients exhibit mutations in the major capsid protein (VP1) surface loops.
Purpose of the Study:
- To investigate if VP1 mutations in JCV strains from PML patients contribute to immune evasion.
- To assess the potential of JC polyomavirus virus-like particle (VLP) vaccination in overcoming neutralizing antibody deficiencies.
Main Methods:
- Neutralization serology was performed on plasma samples from PML patients and healthy individuals against wild-type and PML-mutant JCV strains.
- Mice were immunized with JCV VLPs to assess the development and closure of neutralizing "blind spots".
- A PML patient received an experimental JCV VLP vaccine, and neutralizing titers against cognate PML-mutant JCV were measured.
Main Results:
- Plasma from PML patients failed to neutralize patient-cognate PML-mutant JCV strains, unlike wild-type JCV.
- Healthy individuals' plasma generally cross-neutralized all tested JCV variants.
- Mice showed initial neutralizing "blind spots" that resolved after booster immunizations.
- The PML patient exhibited a significantly increased neutralizing titer against her PML-mutant JCV after VLP vaccination.
Conclusions:
- Deficient humoral immunity against specific JCV variants is a common feature in PML pathogenesis.
- JC polyomavirus VLP vaccination can enhance neutralizing antibody responses, potentially overcoming humoral deficiencies.
- JCV VLP vaccination holds promise as a strategy to prevent PML development.
Related Concept Videos
Viral Mutations
Cytomegalovirus Disease
Inhibitors of Viral Protein Synthesis

